| License: Creative Commons Attribution 4.0 PDF - Published Version (930kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-448704
- DOI to cite this document:
- 10.5283/epub.44870
Wolff, Daniel ; Wagner-Drouet, Eva Maria 
; Teschner, Daniel ; Wolschke, Christine ; Schäfer-Eckart, Kerstin ; Gärtner, Johannes ; Mielke, Stephan ; Schreder, Martin ; Kobbe, Guido ; Hilgendorf, Inken ; Klein, Stefan ; Verbeek, Mareike ; Ditschkowski, Markus ; Koch, Martina ; Lindemann, Monika ; Schmidt, Traudel ; Rascle, Anne ; Barabas, Sascha ; Deml, Ludwig ; Wagner, Ralf
; Teschner, Daniel ; Wolschke, Christine ; Schäfer-Eckart, Kerstin ; Gärtner, Johannes ; Mielke, Stephan ; Schreder, Martin ; Kobbe, Guido ; Hilgendorf, Inken ; Klein, Stefan ; Verbeek, Mareike ; Ditschkowski, Markus ; Koch, Martina ; Lindemann, Monika ; Schmidt, Traudel ; Rascle, Anne ; Barabas, Sascha ; Deml, Ludwig ; Wagner, Ralf 
Abstract
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-gamma ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in ...
Owner only: item control page
Download Statistics